New research has identified a connection between inflammatory bowel disease and reduced activation of TGR5, a bile acid receptor that plays a key role in metabolic and immune regulation. The findings, published in EMJ, suggest that altered bile acid profiles in IBD patients may contribute to ongoing inflammatory activity in the gut.
Background Context
TGR5, also known as G protein-coupled bile acid receptor 1 (GPBAR1), is expressed throughout the gastrointestinal tract and immune cells. This receptor responds to bile acids and helps regulate inflammation, gut motility, and metabolic processes. Bile acids, traditionally understood as digestive molecules, are increasingly recognised for their signalling functions in intestinal health. In inflammatory bowel disease, the gut microbiome and bile acid metabolism are frequently disrupted, though the clinical significance of these changes has remained unclear. Understanding how bile acid signalling pathways function in IBD could reveal new therapeutic targets for managing intestinal inflammation.
Key Findings
The study authors found that patients with inflammatory bowel disease showed reduced activation of the TGR5 receptor compared to healthy controls. This reduction in receptor activity was accompanied by measurable changes in bile acid composition within the intestinal environment. The research team observed that these altered bile acid profiles correlated with the degree of inflammatory activity present in affected tissue. Patients with more active disease demonstrated greater deviations from normal bile acid patterns, suggesting a potential link between bile acid signalling dysfunction and disease severity. The authors noted that TGR5 typically exerts anti-inflammatory effects when activated by specific bile acids, and its reduced function in IBD patients may contribute to persistent inflammation and loss of intestinal immune homeostasis.
Clinical Relevance
These findings add to growing evidence that bile acid metabolism plays an important role in IBD pathophysiology beyond its digestive functions. For gastroenterologists and IBD specialists, understanding the interplay between bile acid profiles and receptor activation may inform future approaches to disease monitoring and treatment. The research suggests that restoring normal bile acid signalling could represent a novel avenue for therapeutic intervention, though further clinical investigation will be required to determine whether targeting TGR5 activation offers practical benefits for patients. For individuals living with Crohn’s disease or ulcerative colitis, this work underscores the complex metabolic changes that accompany intestinal inflammation.
Reference
Inflammatory Bowel Disease Linked to Reduced TGR5 Activation. EMJ Gastroenterology. 2025. Available at: https://www.emjreviews.com/gastroenterology/news/inflammatory-bowel-disease-linked-to-reduced-tgr5-activation/
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.